Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Coleman

Showing results (311-320 of 510) with videos related to

Pageof 51
Sort By:
BMJ Open|November 6, 2020
Quality evaluation of case series describing four-factor prothrombin complex concentrate in oral factor Xa inhibitor-associated bleeding: a systematic reviewOlivia S Costa, William L Baker, Yuani Roman-Morillo, et al.
Nature Neuroscience|May 6, 2022
Genetics and neurobiology of eating disordersCynthia M Bulik, Jonathan R I Coleman, J Andrew Hardaway, et al.
Journal of Market Access & Health Policy|February 19, 2019
Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillationCraig I Coleman, Jean-Baptiste Briere, Laurent Fauchier, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 25, 2019
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery diseaseCraig I Coleman, William L Baker, Anna-Katharina Meinecke, et al.
Pharmacotherapy|January 1, 2019
Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial FibrillationBrandon K Martinez, William L Baker, Nitesh A Sood, et al.
Pharmacotherapy|August 23, 2016
Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary EmbolismErin R Weeda, Christine G Kohn, W Frank Peacock, et al.
Diabetes, Obesity & Metabolism|May 18, 2019
Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetesWilliam L Baker, Jan Beyer-Westendorf, Thomas J Bunz, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|May 27, 2016
External Validation of the Hestia Criteria for Identifying Acute Pulmonary Embolism Patients at Low Risk of Early MortalityErin R Weeda, Christine G Kohn, W Frank Peacock, et al.
Current Medical Research and Opinion|November 23, 2017
Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillationScott Kaatz, Craig I Coleman, Brahim Bookhart, et al.
Psychological Science|April 18, 2020
Comparison of Adopted and Nonadopted Individuals Reveals Gene-Environment Interplay for Education in the UK BiobankRosa Cheesman, Avina Hunjan, Jonathan R I Coleman, et al.
Pageof 51

Showing results (311-320 of 510) with videos related to

Sort By:
Pageof 51
BMJ Open|November 6, 2020
Quality evaluation of case series describing four-factor prothrombin complex concentrate in oral factor Xa inhibitor-associated bleeding: a systematic reviewOlivia S Costa, William L Baker, Yuani Roman-Morillo, et al.
Nature Neuroscience|May 6, 2022
Genetics and neurobiology of eating disordersCynthia M Bulik, Jonathan R I Coleman, J Andrew Hardaway, et al.
Journal of Market Access & Health Policy|February 19, 2019
Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillationCraig I Coleman, Jean-Baptiste Briere, Laurent Fauchier, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 25, 2019
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery diseaseCraig I Coleman, William L Baker, Anna-Katharina Meinecke, et al.
Pharmacotherapy|January 1, 2019
Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial FibrillationBrandon K Martinez, William L Baker, Nitesh A Sood, et al.
Pharmacotherapy|August 23, 2016
Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary EmbolismErin R Weeda, Christine G Kohn, W Frank Peacock, et al.
Diabetes, Obesity & Metabolism|May 18, 2019
Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetesWilliam L Baker, Jan Beyer-Westendorf, Thomas J Bunz, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|May 27, 2016
External Validation of the Hestia Criteria for Identifying Acute Pulmonary Embolism Patients at Low Risk of Early MortalityErin R Weeda, Christine G Kohn, W Frank Peacock, et al.
Current Medical Research and Opinion|November 23, 2017
Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillationScott Kaatz, Craig I Coleman, Brahim Bookhart, et al.
Psychological Science|April 18, 2020
Comparison of Adopted and Nonadopted Individuals Reveals Gene-Environment Interplay for Education in the UK BiobankRosa Cheesman, Avina Hunjan, Jonathan R I Coleman, et al.
Pageof 51